
KARBF
Healthcare · Drug Manufacturers - Specialty & Generic · $1.52B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 25, 2022 | Before the open | 0.23 | -0.48 | -308.7% |
| Oct 27, 2021 | After the close | 0.05 | 0.20 | +300.0% |
| Jul 21, 2021 | After the close | 0.28 | -0.10 | -135.7% |
| Apr 21, 2021 | Before the open | 0.55 | 0.24 | -56.4% |
| Feb 18, 2021 | Before the open | 0.48 | 0.71 | +47.9% |
| Oct 29, 2020 | After the close | 0.44 | 0.66 | +50.0% |
| Jul 20, 2020 | After the close | 0.49 | 0.17 | -65.3% |
| Apr 29, 2020 | Before the open | — | 0.01 | — |
| Feb 18, 2020 | After the close | 0.20 | 0.04 | -80.1% |
| Nov 14, 2019 | After the close | — | 0.16 | — |
| Jul 18, 2019 | After the close | 0.47 | 0.17 | -63.8% |
| Apr 25, 2019 | After the close | — | 0.24 | — |
| Feb 13, 2019 | After the close | 0.43 | 0.16 | -62.8% |
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid…
| Oct 28, 2018 | After the close | 0.25 | 0.33 | +32.0% |
| Jul 18, 2018 | After the close | — | 0.04 | — |
| Apr 25, 2018 | After the close | — | 0.43 | — |
| Feb 21, 2018 | After the close | — | 0.05 | — |